These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36201165)

  • 1. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
    Marmouset V; Decroocq J; Garciaz S; Etienne G; Belhabri A; Bertoli S; Gastaud L; Simand C; Chantepie S; Uzunov M; Genthon A; Berthon C; Chiche E; Dumas PY; Vargaftig J; Salmeron G; Lemasle E; Tavernier E; Delage J; Loirat M; Morineau N; Blanc-Durand F; Pautier P; Vergé V; Auger N; Thomas M; Stefani L; Lepelley M; Boyer T; Thepot S; Gourin MP; Bourquard P; Duchmann M; Morice PM; Michallet M; Adès L; Fenaux P; Récher C; Dombret H; Pagès A; Marzac C; Leary A; Micol JB;
    Clin Cancer Res; 2022 Dec; 28(23):5211-5220. PubMed ID: 36201165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
    Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
    Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
    Todisco E; Gigli F; Mantiero M; Sammassimo S; Pastano R; Ronchini C; Parma G; Lapresa MT; Iori AP; Bertolini F; Corsini C; Gregato G; Poletti C; Colombo N; Tarella C
    Int J Cancer; 2021 Jan; 148(1):170-177. PubMed ID: 32856727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid neoplasms post PARP inhibitors for ovarian cancer.
    Caruso G; Gigli F; Parma G; Lapresa M; Derio S; Palaia I; Colombo N
    Int J Gynecol Cancer; 2023 Apr; 33(4):598-606. PubMed ID: 36707087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
    Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.
    Gupta S; Hanna PE; Ouyang T; Yamada KS; Sawtell R; Wang Q; Katz-Agranov N; Feghali L; Krasner CN; Bouberhan S; Castro CM; Sise ME
    J Natl Cancer Inst; 2023 Jul; 115(7):831-837. PubMed ID: 37074956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
    Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
    Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
    Gauduchon T; Kfoury M; Lorusso D; Floquet A; Ventriglia J; Salaun H; Moubarak M; Rivoirard R; Polastro L; Favier L; You B; Berton D; de la Motte Rouge T; Mansi L; Abdeddaim C; Prulhiere K; Lancry Lecomte L; Provansal M; Dalban C; Ray-Coquard I
    Gynecol Oncol; 2023 Jun; 173():98-105. PubMed ID: 37105063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.